Abstract | BACKGROUND: METHODS: This was an open-label, single-arm study conducted in Latin America from February 2012 to May 2013. Patients with open-angle glaucoma or ocular hypertension who were intolerant of latanoprost 0.005 % were transitioned to receive once-daily BAK-free travoprost 0.004 % containing polyquaternium-1 (Travatan® preserved with POLYQUAD® [PQ], Alcon Laboratories, Inc; Fort Worth, TX) for 12 weeks. Mean change in IOP from baseline (primary efficacy endpoint) and the percentage of patients who achieved a target IOP of ≤18 mmHg were evaluated at all on- therapy visits. Ocular hyperemia, patient preference, and self-projected adherence were assessed at week 12. Adverse events (AEs) were monitored throughout the study. RESULTS: All enrolled patients were included in the analysis (n = 191); the majority of patients (90.6 %, n = 173/191) completed the study. Mean (SD) patient age was 67.5 (11.3) years, and mean baseline IOP was 14.8 mmHg. Mean IOP was reduced by 0.94 mmHg at week 6 and by 1.09 mmHg at week 12 (P < 0.001 for both). A greater percentage of patients achieved a target IOP of ≤18 mmHg at week 6 (93.1 %; n = 163/175) and week 12 (93.3 %; n = 166/178) compared with baseline (89.5 %; n = 171/191). There was a 10.5 % increase in the percentage of patients with "none/trace" amounts of hyperemia. Most patients preferred the study medication (81.5 %; n = 141/173) and were confident that they would adhere to their preferred medication (90.8 %; n = 157/173). No serious AEs were reported, and eye irritation (3.7 %; n = 7/191) was the most common treatment-related AE. CONCLUSIONS: TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01510145.
|
Authors | Joao F Lopes, Douglas A Hubatsch, Patricia Amaris |
Journal | BMC ophthalmology
(BMC Ophthalmol)
Vol. 15
Pg. 166
(Nov 12 2015)
ISSN: 1471-2415 [Electronic] England |
PMID | 26563363
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Benzalkonium Compounds
- Preservatives, Pharmaceutical
- Prostaglandins F, Synthetic
- Latanoprost
- Travoprost
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antihypertensive Agents
(adverse effects, therapeutic use)
- Benzalkonium Compounds
- Conjunctival Diseases
(chemically induced)
- Corneal Diseases
(chemically induced)
- Drug Substitution
- Female
- Glaucoma, Open-Angle
(drug therapy)
- Humans
- Hyperemia
(chemically induced)
- Intraocular Pressure
(drug effects)
- Latanoprost
- Male
- Middle Aged
- Ocular Hypertension
(drug therapy)
- Preservatives, Pharmaceutical
- Prostaglandins F, Synthetic
(therapeutic use)
- Tonometry, Ocular
- Travoprost
(adverse effects, therapeutic use)
- Young Adult
|